OBJECTIVE: To determine the efficacy and outcome from radical vaginal trachelectomy (RVT) compared to a matched group of patients undergoing radical hysterectomy for small early stage cervical cancer. METHODS: All patient data were entered prospectively. Patients wishing preservation of fertility with cervical cancer, tumor <2 cm, and not meeting the definition of microinvasive cancer were offered RVT. The outcomes were compared to a matched group of patients who underwent radical hysterectomy for stage IA/IB cervical cancer. Groups were matched 1:1 for age (+/-5 years), tumor size (+/-1 mm), histology, grade, depth of invasion (+/-1 mm), presence of capillary lymphatic space invasion, pelvic lymph node metastasis, and adjuvant radiotherapy. RESULTS: A total of 137 patients underwent RVT between 1994 and 2007. Of them, 90 patients were successfully matched. Median tumor size was microscopic. Moreover, 43% and 49% were squamous and had adeno/adenosquamous histology. Median depth of invasion was 3.1 mm. Capillary lymphatic space invasion was present in 68% of cases. Of the tumors, 60% were grade 1, 29% were grade 2, and 11% were grade 3. After a median follow-up of 51 and 58 months, 5 and 1 recurrences were diagnosed in the RVT and radical hysterectomy groups, respectively. Five-year recurrence-free survival rates were present in 95% and 100% of the groups, respectively (p=0.17). In addition, 3 and 1 deaths occurred in the RVT and radical hysterectomy groups, resulting in 5-year survival rates of 99% and 100%, respectively (p=0.55). CONCLUSIONS: RVT seems to be the procedure of choice for women with small early stage cervical cancers wishing to preserve fertility.
OBJECTIVE: To determine the efficacy and outcome from radical vaginal trachelectomy (RVT) compared to a matched group of patients undergoing radical hysterectomy for small early stage cervical cancer. METHODS: All patient data were entered prospectively. Patients wishing preservation of fertility with cervical cancer, tumor <2 cm, and not meeting the definition of microinvasive cancer were offered RVT. The outcomes were compared to a matched group of patients who underwent radical hysterectomy for stage IA/IB cervical cancer. Groups were matched 1:1 for age (+/-5 years), tumor size (+/-1 mm), histology, grade, depth of invasion (+/-1 mm), presence of capillary lymphatic space invasion, pelvic lymph node metastasis, and adjuvant radiotherapy. RESULTS: A total of 137 patients underwent RVT between 1994 and 2007. Of them, 90 patients were successfully matched. Median tumor size was microscopic. Moreover, 43% and 49% were squamous and had adeno/adenosquamous histology. Median depth of invasion was 3.1 mm. Capillary lymphatic space invasion was present in 68% of cases. Of the tumors, 60% were grade 1, 29% were grade 2, and 11% were grade 3. After a median follow-up of 51 and 58 months, 5 and 1 recurrences were diagnosed in the RVT and radical hysterectomy groups, respectively. Five-year recurrence-free survival rates were present in 95% and 100% of the groups, respectively (p=0.17). In addition, 3 and 1 deaths occurred in the RVT and radical hysterectomy groups, resulting in 5-year survival rates of 99% and 100%, respectively (p=0.55). CONCLUSIONS: RVT seems to be the procedure of choice for women with small early stage cervical cancers wishing to preserve fertility.
Authors: Gloria Salvo; Pedro T Ramirez; Mario Leitao; David Cibula; Christina Fotopoulou; Ali Kucukmetin; Gabriel Rendon; Myriam Perrotta; Reitan Ribeiro; Marcelo Vieira; Glauco Baiocchi; Henrik Falconer; Jan Persson; Xiaohua Wu; Mihai Emil Căpilna; Nicolae Ioanid; Berit Jul Mosgaard; Igor Berlev; Dilyara Kaidarova; Alexander Babatunde Olawaiye; Kaijiang Liu; Silvana Pedra Nobre; Roman Kocian; Srdjan Saso; Stuart Rundle; Florencia Noll; Audrey Tieko Tsunoda; Kolbrun Palsdottir; Xiaoqi Li; Elena Ulrikh; Zhijun Hu; Rene Pareja Journal: Int J Gynecol Cancer Date: 2019-02-13 Impact factor: 3.437
Authors: Alpa M Nick; Michael M Frumovitz; Pamela T Soliman; Kathleen M Schmeler; Pedro T Ramirez Journal: Gynecol Oncol Date: 2011-10-27 Impact factor: 5.482
Authors: Evan S Smith; Ashley S Moon; Robin O'Hanlon; Mario M Leitao; Yukio Sonoda; Nadeem R Abu-Rustum; Jennifer J Mueller Journal: Obstet Gynecol Date: 2020-09 Impact factor: 7.623
Authors: Katherine Downey; John H Shepherd; Ayoma D Attygalle; Steve Hazell; Veronica A Morgan; Sharon L Giles; Thomas E J Ind; Nandita M Desouza Journal: Gynecol Oncol Date: 2014-02-26 Impact factor: 5.482